• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The systems of metastatic potential prediction in pheochromocytoma and paraganglioma.嗜铬细胞瘤和副神经节瘤转移潜能预测系统。
Am J Cancer Res. 2020 Mar 1;10(3):769-780. eCollection 2020.
2
Validation and Evaluation of 5 Scoring Systems for Predicting Metastatic Risk in Pheochromocytoma and Paraganglioma.验证和评估 5 种评分系统在预测嗜铬细胞瘤和副神经节瘤转移风险中的作用。
Am J Surg Pathol. 2024 Jul 1;48(7):855-865. doi: 10.1097/PAS.0000000000002238. Epub 2024 May 7.
3
Risk Stratification on Pheochromocytoma and Paraganglioma from Laboratory and Clinical Medicine.嗜铬细胞瘤和副神经节瘤的实验室及临床医学风险分层
J Clin Med. 2018 Aug 27;7(9):242. doi: 10.3390/jcm7090242.
4
Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma/paraganglioma: A cohort study.与嗜铬细胞瘤/副神经节瘤转移和复发进展相关的形态学和免疫组织化学特征:一项队列研究。
Ann Diagn Pathol. 2022 Oct;60:151981. doi: 10.1016/j.anndiagpath.2022.151981. Epub 2022 May 28.
5
Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.嗜铬细胞瘤和副神经节瘤转移潜能预测病理分级系统的验证
PLoS One. 2017 Nov 8;12(11):e0187398. doi: 10.1371/journal.pone.0187398. eCollection 2017.
6
DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers.DNA 甲基化谱分析在嗜铬细胞瘤和副神经节瘤中的诊断和预后标志物。
Clin Cancer Res. 2015 Jul 1;21(13):3020-30. doi: 10.1158/1078-0432.CCR-14-2804. Epub 2015 Mar 30.
7
Lesion-based indicators predict long-term outcomes of pheochromocytoma and paraganglioma- SIZEPASS.基于病灶的指标预测嗜铬细胞瘤和副神经节瘤的长期预后 - SIZEPASS。
Front Endocrinol (Lausanne). 2023 Aug 4;14:1235243. doi: 10.3389/fendo.2023.1235243. eCollection 2023.
8
[Clinical profile of pheochromocytoma and paraganglioma with normal plasma free metanephrines].血浆游离甲氧基肾上腺素正常的嗜铬细胞瘤和副神经节瘤的临床特征
Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Aug 18;52(4):614-620. doi: 10.19723/j.issn.1671-167X.2020.04.003.
9
The Value of Histological Algorithms to Predict the Malignancy Potential of Pheochromocytomas and Abdominal Paragangliomas-A Meta-Analysis and Systematic Review of the Literature.组织学算法预测嗜铬细胞瘤和腹部副神经节瘤恶性潜能的价值——一项文献的荟萃分析和系统评价
Cancers (Basel). 2019 Feb 15;11(2):225. doi: 10.3390/cancers11020225.
10
MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression.MYO5B 突变在嗜铬细胞瘤/副神经节瘤中促进肿瘤进展。
PLoS Genet. 2020 Jun 8;16(6):e1008803. doi: 10.1371/journal.pgen.1008803. eCollection 2020 Jun.

引用本文的文献

1
CT features predict tumour invasion of adrenal pheochromocytoma: a retrospective observational study.CT特征预测肾上腺嗜铬细胞瘤的肿瘤侵犯:一项回顾性观察研究
BMC Med Imaging. 2025 Jul 14;25(1):281. doi: 10.1186/s12880-025-01827-6.
2
CT-based radiomics deep learning signatures for non-invasive prediction of metastatic potential in pheochromocytoma and paraganglioma: a multicohort study.基于CT的影像组学深度学习特征用于嗜铬细胞瘤和副神经节瘤转移潜能的无创预测:一项多队列研究
Insights Imaging. 2025 Apr 5;16(1):81. doi: 10.1186/s13244-025-01952-4.
3
Pheochromocytoma in MEN2.多发性内分泌腺瘤病2型中的嗜铬细胞瘤
Recent Results Cancer Res. 2025;223:211-235. doi: 10.1007/978-3-031-80396-3_8.
4
Prognostic significance of Ki-67 in assessing the risk of progression, relapse or metastasis in pheochromocytomas and paragangliomas.Ki-67在评估嗜铬细胞瘤和副神经节瘤进展、复发或转移风险中的预后意义。
Ann Med. 2025 Dec;57(1):2478312. doi: 10.1080/07853890.2025.2478312. Epub 2025 Mar 13.
5
Urinary Dopamine Levels Can Predict the Avidity of Post-Therapy [I]MIBG Scintigraphy in Unresectable or Metastatic Pheochromocytomas and Paragangliomas: A Preliminary Clinical Study.尿多巴胺水平可预测不可切除或转移性嗜铬细胞瘤和副神经节瘤治疗后[I]间碘苄胍闪烁显像的摄取情况:一项初步临床研究。
Pharmaceuticals (Basel). 2025 Jan 26;18(2):165. doi: 10.3390/ph18020165.
6
Surgical anesthesia in a patient with a pheochromocytoma crisis supported by ECMO: a case report.体外膜肺氧合(ECMO)支持下嗜铬细胞瘤危象患者的手术麻醉:一例报告
J Cardiothorac Surg. 2024 Dec 20;19(1):674. doi: 10.1186/s13019-024-03177-w.
7
Long-term outcomes and prognostic factors of metastatic or recurrent pheochromocytoma and paraganglioma: a 20-year review in a single institution.在单一机构的 20 年回顾中,转移性或复发性嗜铬细胞瘤和副神经节瘤的长期结果和预后因素。
Sci Rep. 2024 Nov 2;14(1):26456. doi: 10.1038/s41598-024-75354-9.
8
Usefulness of the Primary Tumor Standardized Uptake Value of Iodine-123 Metaiodobenzylguanidine for Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma.碘-123间碘苄胍原发性肿瘤标准化摄取值对预测嗜铬细胞瘤和副神经节瘤转移潜能的价值
Mol Imaging Biol. 2024 Dec;26(6):1005-1015. doi: 10.1007/s11307-024-01952-8. Epub 2024 Sep 18.
9
[Metastatic risk factors in pheochromocytoma/paraganglioma].[嗜铬细胞瘤/副神经节瘤的转移危险因素]
Probl Endokrinol (Mosk). 2023 Oct 4;70(2):37-45. doi: 10.14341/probl13331.
10
Comprehensive Investigation of Angiogenesis, PASS Score and Immunohistochemical Factors in Risk Assessment of Malignancy for Paraganglioma and Pheochromocytoma.副神经节瘤和嗜铬细胞瘤恶性风险评估中血管生成、PASS评分及免疫组化因素的综合研究
Diagnostics (Basel). 2024 Apr 19;14(8):849. doi: 10.3390/diagnostics14080849.

本文引用的文献

1
Von Hippel-Lindau "Black Forest" mutation inherited in a large Chinese family.在中国一个大家庭中遗传性的希佩尔-林道“黑森林”突变。
Gland Surg. 2019 Aug;8(4):343-353. doi: 10.21037/gs.2019.08.03.
2
Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma.整合多组学分析确定了转移性嗜铬细胞瘤/副神经节瘤的预后 miRNA 特征和可靶向的 miR-21-3p/TSC2/mTOR 轴。
Theranostics. 2019 Jul 9;9(17):4946-4958. doi: 10.7150/thno.35458. eCollection 2019.
3
Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine.转移性嗜铬细胞瘤和副神经节瘤患者的靶向放射性核素治疗:从低比活度到高比活度碘-131间碘苄胍
Cancers (Basel). 2019 Jul 20;11(7):1018. doi: 10.3390/cancers11071018.
4
Pheochromocytomas and Paragangliomas as Causes of Endocrine Hypertension.嗜铬细胞瘤和副神经节瘤作为内分泌性高血压的病因
Front Endocrinol (Lausanne). 2019 Jun 4;10:333. doi: 10.3389/fendo.2019.00333. eCollection 2019.
5
MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.miR-210 可能是恶性嗜铬细胞瘤和副神经节瘤的术前生物标志物。
J Surg Res. 2019 Nov;243:1-7. doi: 10.1016/j.jss.2019.04.086. Epub 2019 May 27.
6
Emerging molecular markers of metastatic pheochromocytomas and paragangliomas.转移性嗜铬细胞瘤和副神经节瘤的新兴分子标志物。
Ann Endocrinol (Paris). 2019 Jun;80(3):159-162. doi: 10.1016/j.ando.2019.04.003. Epub 2019 Apr 11.
7
Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies.嗜铬细胞瘤和副神经节瘤:从基因多样性到靶向治疗
Cancers (Basel). 2019 Mar 28;11(4):436. doi: 10.3390/cancers11040436.
8
Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.嗜铬细胞瘤和副神经节瘤的基因型-表型相关性:系统评价和个体患者荟萃分析。
Endocr Relat Cancer. 2019 May;26(5):539-550. doi: 10.1530/ERC-19-0024.
9
COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.COPPS 评分综合了病理特征、PS100 和 SDHB 缺失,可预测嗜铬细胞瘤/副神经节瘤的转移风险和无进展生存期。
Virchows Arch. 2019 Jun;474(6):721-734. doi: 10.1007/s00428-019-02553-5. Epub 2019 Mar 13.
10
The Value of Histological Algorithms to Predict the Malignancy Potential of Pheochromocytomas and Abdominal Paragangliomas-A Meta-Analysis and Systematic Review of the Literature.组织学算法预测嗜铬细胞瘤和腹部副神经节瘤恶性潜能的价值——一项文献的荟萃分析和系统评价
Cancers (Basel). 2019 Feb 15;11(2):225. doi: 10.3390/cancers11020225.

嗜铬细胞瘤和副神经节瘤转移潜能预测系统。

The systems of metastatic potential prediction in pheochromocytoma and paraganglioma.

作者信息

Wang Yong, Li Minghao, Deng Hao, Pang Yingxian, Liu Longfei, Guan Xiao

机构信息

Department of Urology, Xiangya Hospital, Central South University NO. 87 Xiangya Road, Changsha 410008, Hunan, P. R. China.

National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University No. 87 Xiangya Road, Changsha 410008, Hunan, P. R. China.

出版信息

Am J Cancer Res. 2020 Mar 1;10(3):769-780. eCollection 2020.

PMID:32266090
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7136918/
Abstract

Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumors that arising from the adrenal medulla or extra-adrenal autonomic ganglia. Traditionally, PPGL was classified as benign or malignant based on the presence of distant metastasis at the time of initial surgery. However, according to WHO 2017 Classification of Tumors of Endocrine Organs, all PPGL has metastatic potential. The term "metastatic" is used, replacing "malignant" in this group of tumors. The prediction of PPGL's metastatic potential is a clinical concern, although many relevant indicators such as genetics, histology, pathology and molecular biology markers have been proved to be related to the metastasis of PPGL, but none of them is 100% predictive; various types of prediction systems had been created, but previous studies had demonstrated that they still need to be validated in multicenter studies. There is no unified clinical standard to differentiate metastatic from non-metastatic and a highly effective prediction system is of urgent need. In this review, we summarized all reported prediction systems, including the PASS system, the GAPP system, the COPPs system and the ASES system. Additional potential indicators that related to metastatic PPGL were also introduced.

摘要

嗜铬细胞瘤和副神经节瘤(PPGL)是起源于肾上腺髓质或肾上腺外自主神经节的罕见神经内分泌肿瘤。传统上,PPGL根据初次手术时是否存在远处转移分为良性或恶性。然而,根据世界卫生组织2017年内分泌器官肿瘤分类,所有PPGL都有转移潜能。在这组肿瘤中,使用“转移性”一词取代“恶性”。PPGL转移潜能的预测是一个临床关注点,尽管许多相关指标如遗传学、组织学、病理学和分子生物学标志物已被证明与PPGL的转移有关,但它们都不是100%具有预测性;已经创建了各种类型的预测系统,但先前的研究表明它们仍需要在多中心研究中进行验证。目前尚无区分转移性和非转移性的统一临床标准,急需一个高效的预测系统。在本综述中,我们总结了所有已报道的预测系统,包括PASS系统、GAPP系统、COPPs系统和ASES系统。还介绍了与转移性PPGL相关的其他潜在指标。